De-risking the clinical development of cholesteryl ester transfer protein inhibitors: how much is good enough?

被引：6
|
作者：
Arsenault, Benoit J. [2 ]
Boekholdt, S. Matthijs [3 ]
Tardif, Jean-Claude [2 ]
Kastelein, John J. P. [1 ]
机构：
[1] Univ Amsterdam, Acad Med Ctr, Dept Vasc Med, NL-1105 AZ Amsterdam, Netherlands
[2] Univ Montreal, Montreal Heart Inst, Quebec City, PQ, Canada
[3] Univ Amsterdam, Acad Med Ctr, Dept Cardiol, NL-1105 AZ Amsterdam, Netherlands
来源：
EUROPEAN HEART JOURNAL | 2012年 / 33卷 / 13期
关键词：
OFF-TARGET TOXICITY; ENDOTHELIAL DYSFUNCTION; TORCETRAPIB; ALDOSTERONE; DISEASE; SAFETY;
D O I：
10.1093/eurheartj/ehr408
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：1548 / 1550
页数：3
相关论文
共 50 条
  • [31] Mechanism of Inhibition of Cholesteryl Ester Transfer Protein by Small Molecule Inhibitors
    Chirasani, Venkat R.
    Sankar, Revathi
    Senapati, Sanjib
    [J]. JOURNAL OF PHYSICAL CHEMISTRY B, 2016, 120 (33): : 8254 - 8263
  • [32] Future of Cholesteryl Ester Transfer Protein (CETP) Inhibitors: A Pharmacological Perspective
    Mohammadpour, Amir Hooshang
    Akhlaghi, Fatemeh
    [J]. CLINICAL PHARMACOKINETICS, 2013, 52 (08) : 615 - 626
  • [33] Novel Cholesteryl Ester Transfer Protein Inhibitors: Promising Therapy for Dyslipidemia?
    Devaraj, Sridevi
    Jialal, Ishwarlal
    [J]. METABOLIC SYNDROME AND RELATED DISORDERS, 2011, 9 (03) : 163 - 165
  • [34] Therapy with cholesteryl ester transfer protein (CETP) inhibitors and diabetes risk
    Masson, W.
    Lobo, M.
    Siniawski, D.
    Huerin, M.
    Molinero, G.
    Valero, R.
    Nogueira, J. P.
    [J]. DIABETES & METABOLISM, 2018, 44 (06) : 508 - 513
  • [35] Diphenylpyridylethanamine (DPPE) Derivatives as Cholesteryl Ester Transfer Protein (CETP) Inhibitors
    Harikrishnan, Lalgudi S.
    Finlay, Heather J.
    Qiao, Jennifer X.
    Kamau, Muthoni G.
    Jiang, Ji
    Wang, Tammy C.
    Li, James
    Cooper, Christopher B.
    Poss, Michael A.
    Adam, Leonard P.
    Taylor, David S.
    Chen, Alice Ye A.
    Yin, Xiaohong
    Sleph, Paul G.
    Yang, Richard Z.
    Sitkoff, Doree F.
    Galella, Michael A.
    Nirschl, David S.
    Van Kirk, Katy
    Miller, Arthur V.
    Huang, Christine S.
    Chang, Ming
    Chen, Xue-Qing
    Salvati, Mark E.
    Wexler, Ruth R.
    Lawrence, R. Michael
    [J]. JOURNAL OF MEDICINAL CHEMISTRY, 2012, 55 (13) : 6162 - 6175
  • [36] Cholesteryl Ester Transfer Protein (CETP) Inhibitors: Is There Life After Torcetrapib?
    Neeli, Hemanth
    Rader, Daniel J.
    [J]. CARDIOLOGY CLINICS, 2008, 26 (04) : 537 - +
  • [37] CHOLESTERYL ESTER TRANSFER PROTEIN (CETP) INHIBITORS AND THEIR ROLE IN CARDIOVASCULAR DISORDERS
    Kontush, A.
    [J]. DRUGS OF THE FUTURE, 2011, 36 (05) : 377 - 384
  • [38] Future of Cholesteryl Ester Transfer Protein (CETP) Inhibitors: A Pharmacological Perspective
    Amir Hooshang Mohammadpour
    Fatemeh Akhlaghi
    [J]. Clinical Pharmacokinetics, 2013, 52 : 615 - 626
  • [39] Discovery of Substituted Biphenyl Oxazolidinone Inhibitors of Cholesteryl Ester Transfer Protein
    Thompson, Christopher F.
    Ali, Amjad
    Quraishi, Nazia
    Lu, Zhijian
    Hammond, Milton L.
    Sinclair, Peter J.
    Anderson, Matt S.
    Eveland, Suzanne S.
    Guo, Qiu
    Hyland, Sheryl A.
    Milot, Denise P.
    Sparrow, Carl P.
    Wright, Samuel D.
    [J]. ACS MEDICINAL CHEMISTRY LETTERS, 2011, 2 (06): : 424 - 427
  • [40] Anacetrapib and Dalcetrapib: Two Novel Cholesteryl Ester Transfer Protein Inhibitors
    Miyares, Marta A.
    [J]. ANNALS OF PHARMACOTHERAPY, 2011, 45 (01) : 84 - 94
12345